Keros director sells 2,625 shares under 10b5-1 plan

Keros Therapeutics director Nima Farzan sold shares in a planned trade.

Rhea-AI Filing Summary

Keros Therapeutics director Nima Farzan sold shares in a planned trade. On June 4, 2026, he sold 2,625 shares of Keros Therapeutics common stock in an open-market transaction at a weighted average price of $10.73 per share.

The sale was executed under a Rule 10b5-1 trading plan adopted on December 5, 2025, indicating it was pre-arranged. After these transactions, Farzan directly owns 9,767 shares of Keros Therapeutics common stock.

Insider Trade Summary 10b5-1

Net Seller: 2,625 shares

Net Sell 1 txn

Insider Farzan Nima

Role Director

Sold 2,625 shs ($28K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,625	$10.73	$28K

Holdings After Transaction: Common Stock — 9,767 shares (Direct)

Footnotes (2)

1. F1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 2,625 shares Weighted average sale price: $10.73 per share Post-transaction holdings: 9,767 shares +1 more

4 metrics

Shares sold 2,625 shares Open-market sale on June 4, 2026

Weighted average sale price $10.73 per share Common stock sale on June 4, 2026

Post-transaction holdings 9,767 shares Shares beneficially owned after the sale

Sale price range $10.61–$10.89 per share Multiple trades comprising the 2,625-share sale

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, transaction code S

4 terms

Rule 10b5-1 trading plan regulatory

"The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price"

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

transaction code S regulatory

"transaction_code: S, Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Keros Therapeutics (KROS) report for Nima Farzan?

Keros Therapeutics reported that director Nima Farzan sold 2,625 shares of common stock on June 4, 2026. The sale was an open-market transaction at a weighted average price of $10.73 per share, according to the Form 4 filing.

At what prices did Nima Farzan sell Keros Therapeutics (KROS) shares?

The reported weighted average price for the sale was $10.73 per share. Footnotes state the 2,625 shares were sold in multiple trades at prices ranging from $10.61 to $10.89 per share, all completed on June 4, 2026.

How many Keros Therapeutics (KROS) shares does Nima Farzan hold after the sale?

After the June 4, 2026 sale, director Nima Farzan directly holds 9,767 shares of Keros Therapeutics common stock. This post-transaction ownership figure is reported in the Form 4 under total shares beneficially owned following the reported transaction.

Was the Keros Therapeutics (KROS) insider sale made under a Rule 10b5-1 plan?

Yes. The Form 4 footnotes state that the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Nima Farzan on December 5, 2025. Such plans pre-schedule trades, reducing the significance of short-term market timing.

What type of transaction did Keros Therapeutics (KROS) disclose on the Form 4?

The filing discloses an open-market sale of Keros Therapeutics common stock by director Nima Farzan. The transaction code was S, which indicates a sale in an open-market or private transaction, covering 2,625 shares on June 4, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 04:37 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farzan Nima

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/04/2026		S(1)		2,625	D	$10.73(2)	9,767	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 5, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.61 to $10.89 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Keith Regnante, Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)